Phase II, Open Label, Dose Finding Study of the Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer Compared to a Luteinizing Hormone Releasing Hormone Agonist.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2015
At a glance
- Drugs GTx 758 (Primary) ; Leuprorelin
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors GTx
- 08 May 2013 Tolerability outcomes presented at the 108th Annual Meeting of the American Urological Association.
- 19 Mar 2013 Results presented at the 28th Annual European Association of urology Congress, according to a GTx media release.
- 13 Feb 2013 Results will be presented at the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium according to a GTx media release. Results were also briefly summarised in the media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History